Harrow Health Inc
NASDAQ:HROW

Watchlist Manager
Harrow Health Inc Logo
Harrow Health Inc
NASDAQ:HROW
Watchlist
Price: 42.9 USD -2.23% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Harrow Health Inc?
Write Note

Harrow Health Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Harrow Health Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Harrow Health Inc
NASDAQ:HROW
Additional Paid In Capital
$216.1m
CAGR 3-Years
27%
CAGR 5-Years
17%
CAGR 10-Years
16%
Johnson & Johnson
NYSE:JNJ
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Additional Paid In Capital
$45.9B
CAGR 3-Years
1%
CAGR 5-Years
83%
CAGR 10-Years
41%
Pfizer Inc
NYSE:PFE
Additional Paid In Capital
$93.2B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Additional Paid In Capital
$44.5B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
1%
Eli Lilly and Co
NYSE:LLY
Additional Paid In Capital
$7.3B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
3%
No Stocks Found

Harrow Health Inc
Glance View

Market Cap
1.5B USD
Industry
Pharmaceuticals

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 182 full-time employees. The company went IPO on 2013-02-08. The firm owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. The firm holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals. The firm also owns royalty rights in four clinical stage drug candidates, which are being developed by Surface Ophthalmics and Melt Pharmaceuticals.

HROW Intrinsic Value
45.19 USD
Undervaluation 5%
Intrinsic Value
Price

See Also

What is Harrow Health Inc's Additional Paid In Capital?
Additional Paid In Capital
216.1m USD

Based on the financial report for Sep 30, 2024, Harrow Health Inc's Additional Paid In Capital amounts to 216.1m USD.

What is Harrow Health Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
16%

Over the last year, the Additional Paid In Capital growth was 8%. The average annual Additional Paid In Capital growth rates for Harrow Health Inc have been 27% over the past three years , 17% over the past five years , and 16% over the past ten years .

Back to Top